by David Eyre | Feb 18, 2026 | US & International
This case is important because it allows the Supreme Court to define the point of balance between enforcement of patent rights for medical uses and the competition in the market place for generic pharmaceuticals. Consequently, the ruling of the Supreme Court will have...
by Sean Hutchinson | Feb 5, 2026 | US & International
In many countries, patents are granted for inventions and last for 20 years, subject to payment of renewal fees at regular intervals. However, some countries permit the patent term to be extended provided certain requirements are met. In the UK and the EU, a...
by Chloe Sullivan | Jan 20, 2026 | UPC
To briefly recap the key events leading up to this decision, the US Supreme Court found a lack of enablement when assessing the PCSK9 antibody claims in Amgen’s US patent and the Munich Central Division of the UPC initially revoked the European equivalent based on...
by Carolyn Haywood | Oct 28, 2025 | US & International
In district court litigation, patents can be challenged on any ground, and challenges may be based on any kind of prior art recognised by the patent statutes. Inter partes review (IPR) proceedings are, however, different. They are administrative proceedings in which...
by Carolyn Haywood | Sep 30, 2025 | EPO
Background to the referral The G 1/23 referral came from Board 3.3.03 in the consideration of T 0438/19, an appeal against the decision of an opposition division to reject an opposition against a European patent directed to a material for encapsulating a solar cell...
Recent Comments